

L O N D O N

euroPLX



Business Developer

Vol. 13 #10 | October | 2017

Company News, BD&L People on the Move, 20% New Companies at euroPLX 65!

* Distribution: **Abattis Bioceuticals Corp.** has reached a definitive agreement with **Global Damon Pharma** of South Korea, to distribute and sell Abattis' product lines exclusively in South Korea. The agreement allows GD Pharma to begin sales of Abattis products in South Korea effective immediately. 3 Oct 2017 (www.abattis.com)

* Acquisition: **Abbott** closed the previously announced acquisition of **Alere, Inc.**, on Tuesday, Oct. 3, 2017, following receipt of all regulatory clearances necessary for closing. 29 Sep 2017 (www.abbott.com)

* Collaboration: **Amgen** and **Sincere Pharmaceutical Group** executed an exclusive agreement to co-develop and commercialize four biosimilars in China. The collaboration includes undisclosed biosimilars in the areas of inflammation and oncology. 26 Sep 2017 (www.amgen.com)

* Acquisition: **Avara Pharmaceutical Services** has signed and closed on an agreement with **AstraZeneca** to acquire its Reims, France manufacturing and distribution facility. The company now has eight sites: three in the US, including the corporate HQ's; one in Puerto Rico; one in the UK; one in Ireland; one in Italy and this new additional site in France. 5 Oct 2017 (www.avara.com)

* Licensing: **Basilea Pharmaceutica International Ltd.** has entered into a license agreement with **Shenzhen China Resources Gosun Pharmaceutical Co., Ltd.** for Basilea's antibiotic Zevtera® (ceftobiprole) in China, Hong Kong and Macao. Ceftobiprole is currently approved for sale in 13 European countries and several non-European countries for the treatment of adult patients with community-acquired pneumonia and hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia. 28 Sep 2017 (www.basileapharma.com)

* Acquisition: **Breckenridge Pharmaceutical, Inc.**, a privately-held member of the Esteve Group, has acquired five (5) Abbreviated New Drug Applications from Nostrum Laboratories Inc., a wholly owned subsidiary of **Nostrum Pharmaceuticals, LLC**. Three of the acquired assets are FDA approved and will be sold by Breckenridge under its label. Two of the assets are filed and pending with FDA with anticipated approval dates within the next 12 months. The total generic market value for these products is \$305 Million. The three approved ANDAs are CNS products indicated for the treatment of Attention Deficit Disorders and Narcolepsy Attention Deficit Disorders in various dosage forms. 3 Oct 2017

(www.bpirx.com)

* Marketing and distribution: **Devonian Health Group Inc.**, a clinical stage botanical pharmaceutical corporation focused on developing a unique portfolio of botanical prescription drugs and derma-cosmeceutical products, today announced that it has signed its first exclusive marketing and distribution agreement with **Altius Healthcare Inc.** to distribute its proprietary Purgensis™ anti-aging treatment in Canada. The exclusive distribution agreement includes upfront payment for each treatment as well as up to 25% royalties based on sales. 28 Sep 2017 (groupedevoonian.com)

* License and Distribution: **Foresee Pharmaceuticals Co., Ltd.**, a Taiwan and US-based biopharmaceutical company and **TRPharm**, a leading Turkish biopharmaceutical company, have entered into an exclusive license and distribution agreement for the commercialisation in Turkey and certain Middle East countries of Foresee's FP-001 program, LMIS (Leuprolide Mesylate Injectable Suspension) ready-to-use subcutaneous depot formulations. Under the terms of this partnership, Foresee will receive a combination of milestones payments in addition to a significant share of the product revenue in the territory. TRPharm will cover all

costs for registration and commercialization in the territory. 27 Sep 2017 (www.foresee-pharma.com)

* Acquisition: **Gilead Sciences, Inc.** completed the previously announced transaction for **Dodgers Merger Sub, Inc.**, a wholly-owned subsidiary of Gilead, to acquire **Kite Pharma, Inc.** for \$180 per share, net to the seller in cash, without interest, or approximately \$11.9 billion in the aggregate. Kite is a biopharmaceutical company engaged in the development of innovative cancer immunotherapies with a goal of providing rapid, long-term, durable response and eliminating the burden of chronic care. 3 Oct 2017 (www.gilead.com)

* Acquisition and name change: **Silver Falcon Plc** agreed to acquire **Hemogenyx Pharmaceuticals Limited** for 8m. Hemogenyx Pharmaceuticals Limited is the holding company for **Hemogenyx LLC**, a US based biotechnology company developing therapies to transform bone marrow and blood stem cell transplantation. The Company will then trade under the new company name of **Hemogenyx Pharmaceuticals Plc**. 5 Oct 2017 ()

* Acquisition: **HRA Pharma**, acquired the Compeed® brand from **Cilag GmbH International**, a Johnson & Johnson company. Compeed® provides consumers

with a comprehensive portfolio of products for the relief and treatment of blisters, corns, calluses, cracked skin and cold sores. 21 Sep 2017 (www.hra-pharma.com)

* Acquisition: **Lupin Limited's** US subsidiary, **Lupin, Inc.**, has acquired **Symbiomix Therapeutics, LLC**. Symbiomix is a privately held company focused on bringing innovative therapies to market for gynecologic infections that can have serious health consequences. The acquisition has been made for a cash consideration of USD 150 million including a USD 50 million upfront and other time-based payments. 11 Oct 2017 (www.lupin.com)

* Acquisition: **Mallinckrodt plc** closed the acquisition of **InfaCare Pharmaceutical Corporation**, a privately held specialty pharmaceutical company focused on development and commercialization of proprietary pharmaceuticals for neonatal and pediatric patient populations. 25 Sep 2017 (www.mallinckrodt.com)

* Distribution: **Melinta Therapeutics**, a privately held commercial-stage company developing novel antibiotics to treat serious bacterial infections, announced that the commercialization and distribution agreement with **Eurofarma Laboratórios** for delafloxacin (marketed as Baxdela™ in the U.S.) has been expanded to include 19 countries in South and Central America and the Caribbean. 26 Sep 2017 (www.melinta.com)

* Partnership: **Merz Pharma** and **Teijin Limited**, have entered into a strategic license and co-development agreement for the commercialization of Xeomin® (incobotulinumtoxinA) for Japan. Xeomin® was approved for use in the treatment of patients with dystonia and blepharospasm by the European regulatory authorities in 2005 and by the U.S. FDA in 2010. The product has been

approved for post-stroke spasticity of the upper limb in Europe since 2009, with FDA approval for the adult upper limb spasticity indication granted in 2015. Xeomin® is marketed in 50 countries around the world. 12 Oct 2017 (www.merz.com)

* Name Change: **Nanotherapeutics, Inc.** changed its name to **Ology Bioservices, Inc.** The name change is part of a broader rebranding effort and directly reflects the Company's evolution from a products and formulations company toward its goal of becoming one of the industry's top contract development and manufacturing organizations (CDMO), with differentiated expertise in biologics and vaccines. 2 Oct 2017 (www.nanotherapeutics.com)

BD People on the Move

* Amicus Therapeutics, Inc.: **Michael C. Diem**, MD, who had leadership roles in corporate and business development at AstraZeneca and GlaxoSmithKline, has been appointed as Senior Vice President of Business and Corporate Development. (Press Release 6 Oct 2017)

* Avacta Group plc: Dr **Matthew Vincent**, who led corporate development and therapeutic innovation strategy at Arisaph Pharmaceuticals has been appointed as Vice President Therapeutics Business Development. (Press Release 2 Oct 2017)

* Avillion LLP: **Kathryn J. Gregory**, MBA,, who joined from Seneb BioSciences, an early-stage, rare disease company, has been appointed as Chief Business Officer (CBO). (Press Release 3 Oct 2017)

* Fresenius Kabi: **João Ribeiro**, who has been Market Intelligence & Business Development Manager for Fresenius Kabi Portugal, left

the company as of September 30. (Pers Comm 3 Oct 2017)

* Milrin Pharmaceutical Co. (M) Sdn. Bhd.: **Stephanie Chan**, who has been General Manager for business development matters, left the company. (Corp Comm 25 Sep 2017)

* Rafarm Pharmaceuticals S.A.: **Ilias Papasarantos**, until most recently Business Development Manager at Anfarm Hellas, has been appointed as Business Development Manager for Rafarm UK Limited. (Pers Comm 17 Oct 2017)

* Synthon BV: **Pascal Goris**, who has been Account Manager in Marketing & Sales, left the company. (Pers Comm 3 Oct 2017)

euroPLX Newcomers to euroPLX 65 London (1)

Since 22 years euroPLX is attended by companies that have never had a delegate at any of the previous euroPLX Conference. For euroPLX 65 London more than 20% of the participating companies will be newcomers!

Aksuvital Dogal Urunler Gida Sanayi Ve Ticaret A.s. (www.aksuvital.com.tr) manufactures and sells bee products and other natural functional products, natural food supplements and dermocosmetics under three different brands. The company is based in Istanbul, Turkey.

As a member of the Quantum Pharma Group, **Colonis Pharma Ltd.** (www.colonis.co.uk) is a Winchester, UK based pharmaceutical company who is dedicated to making medicines more manageable for patients and healthcare professionals.

Curida (www.curida.no) is a Contract Development and Manufacturing Organization (CDMO) within the Pharmaceutical industry, based in Elverum, Norway. With over three decades of know-how in Blow-Fill-Seal

(BFS) technology, Curida serves customers ranging from start-up to established pharma companies.

Based in Izmir, Turkey, **Dekim Pharmaceuticals and Chemicals Inc** (www.dekim.com.tr) distributes finished form pharmaceuticals in Turkey and exports to Middle East, North Africa and Eastern Europe. Since 2012 the company has started the agricultural production of pharmaceutical and cosmetic grade plants.

GBT Grupo Biotoscana (www.grupobiotoscana.com) develops, manufactures and commercialises advanced medicines. The company is headquartered in Montevideo, Uruguay, and is present in 10 countries throughout the region. Its main areas of operations are oncology, onco-hematology, severe infectious diseases, genetic and rare conditions as well as immunology and inflammation.

Based in Mumbai, India, **Harman Finochem Ltd.** (www.harmanfinochem.com) specialises in the manufacture and export of more than 45 Active Pharmaceutical Ingredients (APIs) of which 10 are Essential Drugs as per the WHO Model List. The company exports to more than 35 countries across the globe.

Intech Biopharm (www.intechbiopharm.com) is part of the Synmosa Group, one of the leading pharmaceutical companies in Taiwan. Intech Biopharm develops, produces and markets specialized drugs focusing on the respiratory treatment categories.

Wooridul Pharmaceutical Ltd. (www.wooridulpharm.com) was established 60 years ago in Seoul, South Korea. It is a fully integrated pharmaceutical company with own research, production, sales, distribution, and exports. Main products are for the treatment of Alzheimer's disease, epileptics, hypertension, pain, skin disorder, and others. (*to be continued*)